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Abstract: Glucokinase (GK) is expressed in multiple organs and plays a key role in hepatic glucose metabolism and pan-
creatic insulin secretion. GK could indeed serve as pacemaker of glycolysis and could be an attractive target for type 2 
diabetes (T2D). The recent preclinical data of first GK activator RO-28-1675 has opened up a new field of GK activation 
as a powerful tool in T2D therapies. The GK allosteric site is located ~20Å away from glucose binding site. Chemical 
structure of Glucokinase activators (GKA) includes three chemical arms; all consisting of cyclic moiety and joined in a 
shape resembling the letter Y. In this study, comparative docking assessment using Autodock4 revealed that the three 
arms bind to three aromatic/hydrophobic subpockets at the allosteric site. Our dockings have overall consistency with ex-
perimental data in both docking modes and simulated binding free energies, and offer insights on understanding GK/GKA 
interactions and further GKA design. Specifically, for the first pocket, involvement of Arg63 as key residue in two spe-
cific hydrogen-bond formations with all allosteric activators defines the binding feature; for the second pocket, it has the 
most diverse binding interactions, mostly aromatic, hydrophobic and multiple hydrogen bonds. The site has the best po-
tential for further GKA optimization by utilizing aromatic heterocycles and hydrogen bond forming linkers to build the 
GKA 2
nd arm.  
Keywords: Molecular docking, Molecular recognition, Free energy, AutoDock, glucokinase, GKA, Glucokinase activator, 
Allosteric, Drug design. 
INTRODUCTION 
  Glucokinase (GK) is one of the four hexokinase 
isozymes present in hepatocytes and in pancreatic -cells 
that metabolize glucose to glucose-6-phosphate [1]. In pan-
creatic  -cells, GK is the rate limiting enzyme in glucose 
metabolism and determines the rate of glucose induced insu-
lin secretion and acts as an ideal glucose sensor [2]. In liver, 
GK activity determines the rate of glucose usage and glyco-
gen synthesis; it follows Non-Mechaelis-Menton kinetics 
which means that no inhibition of GKs with product of the 
reaction, glucose-6-phosphate [3]. Crystal structure of GK in 
complex with glucose and Glucokinase activator (GKA) 
reveals a palm shape topology which contains two domains 
of unequal size; the large and the small. These two domains 
are separated by a deep cleft, which forms the active site for 
glucose phosphorylation. A hydrophobic allosteric pocket is 
present ~20 Å distal to the catalytic site, which is exposed to 
solvent when the kinase is bound to glucose in its ‘closed’ 
catalytically active state. In glucose unbound form (‘open 
form’), hydrophobic pocket is buried within the opposed 
large and small domains. GKAs bind at allosteric site and 
directly activate GK [4]. The glucose binding site and the 
allosteric binding site of GK are shown in Fig. (1).  
 
 
*Address correspondence to this author at the Division of Medicinal Chem-
istry and Pharmacognosy, College of Pharmacy, The Ohio State University, 
500 West 12
th Ave., Columbus, OH 43210, USA; Tel: 614-247-8786;   
Fax: 614-292-2435; E-mail: li.728@osu.edu 
 
  Type 2 Diabetes (T2D) is characterized by defect in ac-
tion and secretion of insulin; which leads to excessive he-
patic glucose production and decreased glucose-induced re-
lease from the pancreatic –cells. In spite of the efforts of 
many research groups, no single oral antidiabetic drug is 
capable of achieving acceptable, long-lasting glycemic con-
trol [5]. Indeed, the use of combination therapy is thought to 
offer better glycemic control relative to monotherapy but 
there are some unwanted side effects of combination therapy 
[6]. Thus, there is growing need of safe and more efficient 
novel drugs. GK would be an ideal drug target for T2D dis-
eases because of its high impact in glucose homeostasis, and 
its activation results in lower blood glucose level irrespective 
of the cause of hyperglycemia [7]. Discovery and promising 
preclinical data of the first allosteric GK activator RO-28-
1675 has intensifies interest in GKAs [8, 9]. Many research 
groups have reported small molecule glucokinase activators 
which are thought to enhance glycemic control by dual 
mechanism of increased pancreatic insulin secretion and 
increased hepatic glucose metabolism [9-17]. Therefore, the 
ability of GKAs to influence multiple organs could provide 
greater efficacy as a monotherapy. In this study, we report 
comparative docking studies of GKAs. The aim of this study 
is to understand interactions involved in the binding of 
GKAs to glucokinase and to offer insights into activation 
pattern of glucokinase by its allosteric activators. This study 
will provide further understanding of the mechanism of glu-
cokinase activation and would enable the design of new 
GKAs capable of selectively activating GK in the treatment 
of T2D.  
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Fig. (1). Glucokinase is shown in ribbon drawing and glucose and glucokinase allosteric activator are shown in CPK. Glucokinase activator 
binding site is present 20 Å distal to the glucose binding site (catalytic site). 
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A: Class I: Amide-Based Chiral GKAs 
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B: Class II: Amide-based achiral GKAs 
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C: Class III: Urea-derivative GKAs 
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D: Class IV: Miscellaneous GKAs 
 
Ligand Structure 
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METHODS 
Docking Calculations 
  We assembled from literature a list of Glucokinase acti-
vators [9-17]
 and classified them into four structural classes. 
RESP charges for each ligand were calculated at HF/6-
31+G(d) level of theory using Gaussian03 [18]. Sander 
module of Amber9 was used to calculate solvation energy of 
the ligands [19]. All ligands were docked to crystal structure 
of active conformation of human glucokinase (PDB ID: 
1V4S) using AutoDock software, version 4.0. [20, 21]. 
Ligand coordinate files were generated by Insight II 2.1 
package (Biosym Technologies Inc., San Diego, CA, USA). 
All ligands shown in Table 1 were docked to active models 
of the Glucokinase, using the Lamarckian Genetic algorithm 
(LGA) [22]. The grid maps representing the protein were 
calculated using the AutoGrid4. A cubic box was built 
around the protein with 61x61x67 grid points; a spacing of 
0.375 between the grid points was used. The protein was 
centered on the geometric center prior to docking. All calcu-
lations and docking simulations were carried out at Ohio 
Supercomputer Center Glenn Cluster. Resulting conforma-
tions that have less than or equal to 1.5 Å root mean square 
deviation were clustered. In addition to resulting docking 
modes, AutoDock also calculates an affinity constant for 
each ligand-receptor configuration.  
RESULTS 
Binding Pattern of Glucokinase Activators at Allosteric 
Site 
  In this study, flexible-ligand docking was performed us-
ing energetically optimized ligands. Table 1 shows the simu-
lated free energy of binding (Gbind) and experimental EC50 
[9-17]
 values. For the docking studies, we classified GKAs 
into four classes. Class I GKAs includes amide-based chiral 
ligands, this class of activators has flexible three arms con-
taining cyclic moiety. These arms are joined in a shape re-
sembling letter Y. Class II GKAs includes amide-based 
achiral ligands; this class of activators has a multi-substituted 
cyclic ring which connects three arms of the ligands. The 
substitutions on the rings are involved in packing interac-
tions at the allosteric binding site. Class III GKAs includes 
urea-derivatives GKAs; this class resembles class I GKAs in 
structural orientation. Class IV GKAs include miscellaneous 
ligands which contains some other groups relative to other 
classes of GKAs. Overall, all GKAs appear to bind, in a con-
sistent mode, between a large hydrophobic patch consisted 
of two perpendicular -helices (5 and 13) and a well sol-
vated loop connector I (Arg63-Ser64-Thr65-Pro66-Gln67-
Gly68) in the junction of the two GK domains. Whereas in 
GK apo structure, there is no allosteric site as the two -
helices packing to each other in parallel and the loop is only 
partially solvated and tucked in a pseudo-helix form against 
the two helices. These loop residues in other non-allosteric 
hexokinase structures pack closely against neighboring struc-
tural elements all the time. In general, a large number of hy-
drophobic binding interactions contribute to the binding en-
ergies of the activators. The three arms of GKAs fit well in 
the three hydrophobic pockets (Fig. 2A) of the glucokinase 
formed at the allosteric site. Amino acid residues involved in 
binding interactions are shown in Fig. (2B). Hydrophobic 
Pocket 1 contains Val62, Ile159, Val452, Val255 hydropho-
bic amino acids and polar Arg63 amino acid residue. In most 
cases, a defined feature is the two hydrogen bonds between 
Arg63 and GKA. One is Arg63 carbonyl to GKA amide; the 
other is Agr63 amide to the nitrogen of the GKA thiazole. It 
seems that an amide linked to a thiazole or pyridine binds to 
the pocket 1 well. Pro66, Val455 and Tyr215 makes hydro-
phobic pocket 2 and hydrophobic pocket 3 is formed by Molecular Docking Assessment of Glucokinase Activators  Current Chemical Genomics, 2008, Volume 2    81 
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Fig. (2). Hydrophobic pockets of allosteric binding site of GK and binding modes GKAs. A. docked binding pose of class 2 GKAs. B. Amino 
acid residues at binding pockets involved in binding interactions with ligands at allosteric pocket. C1, C2, C3. Overlay of the electrostatic 
potential surface map of hydrophobic pockets 1, 2 and 3 respectively with ligand 1 (class I GK) using APBS. D1, D2, D3. Overlay of the 
electrostatic potential surface map of the hydrophobic pockets 1, 2 and 3 respectively with ligand 9 (class II GK) using APBS. E1, E2, E3. 
Overlay of the electrostatic potential surface map hydrophobic pocket 1, 2 and 3 respectively with ligand 15 (class III GK) using APBS. F1, 
F2, F3. Overlay of the electrostatic potential surface map of pocket1, 2 and 3 respectively with ligand 19 (class IV GK) using APBS. Amino 
acids are represented in line and docked conformations of ligands are shown in ball and stick. Surface color red to blue shows potentials from 
negative to positive. 
Met210, Met235 and Tyr214 amino acid residues. Electro-
static potential surface of allosteric site was generated using 
APBS [23]
 and interactions of the ligand’s arms with their 
respective allosteric hydrophobic pocket are shown in Fig. 
(2) C1-F3. Ligands that pack adequately to these three hy-
drophobic pockets show higher binding energies compared 
to the ligands that lack one of the packing interactions, espe-
cially for the pocket 2. Ligands having three arms show 
more efficient interactions at allosteric binding pocket be-
cause of the proper accommodation of the ligand as com-Molecular Docking Assessment of Glucokinase Activators  Current Chemical Genomics, 2008, Volume 2    83 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Molecular surface of GK shows 3 hydrophobic cavities at allosteric binding site. Ligands with three hydrophobic arms (B) fit more 
efficiently in cavity as compared to ligands with two hydrophobic arms (A). Molecular surface of allosteric site of GK (silver color) and 
ligands (green color) are represented here. Ball and stick rendering of ligands are also shown. 
 
Table 2.  Allosteric Amino Acid Residues Involved in the Binding Interactions with the Ligands 
Residues involved in hydrogen bond  Residues involved in hydrophobic  
interaction (small domain) 
Residues involved in hydrophobic interaction  
(large domain) 
Arg63, Tyr215, Gln98  Val452, Val455, Ala456  Val62, Pro66, Ile159, Met210,Ile211, Tyr214, Met235, Cys220 
 
pared to ligands lacking one of the arms (Fig. 3A and B). 
Involvement of allosteric site residues in different kind of 
interactions with ligands is shown in Table 2.  
Comparative Binding Interactions of GKAs  
Class I: Amide-Based Chiral GKAs 
The three cyclic moieties joined in Y shape contain amide 
linkage along the stem of the Y, the amide NH acts as hy-
drogen bond donor and involved in specific hydrogen bond 
formation with Arg63 backbone carbonyl O. Heterocyclic 
group containing N at position two connected to the amide 
NH of ligand makes another specific hydrogen bond forma-
tion with the Arg63 backbone NH (Fig. 4). This class of 
ligands contains cyclopentyl or cyclohexyl (R3) as one arm 
of the ligand and shows packing in hydrophobic pocket 3 
(Fig.  6A). R3 group nestles between two Met210, Met235 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Binding interactions of ligand 1 (class I GKA), green dotted lines shows hydrogen bonding interactions. Amino acid residues shown 
are involved in van der Walls packing interactions with GK. Ligand 1 is shown in stick and balls, amino acids are shown in licorice view.  84    Current Chemical Genomics, 2008, Volume 2  Kumari and Li 
and Tyr214 side chain at allosteric site. Fig. (4) shows bind-
ing interactions of ligand 1 (class I GKA). Ligands contain-
ing hydrogen bond acceptor group in R2 makes additional 
hydrogen bond formation with Tyr215 and Gln98. Aligned 
binding modes of class I ligands are shown in Fig. (5). 
Ligand 3 shows three hydrogen bond formations with Arg63 
due to presence of ester group in thiazole ring. Val62, Pro66, 
Ile159, Met210, Ile211, Tyr214, Met235, Cys220, Val452, 
Val455, Ala456 are the main residues involved in hydropho-
bic interactions with this class of ligands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Aligned docked mode of ligands of class I GKAs. Ligands 
are shown in lines and amino acid residues are shown in licorice 
display. 
  Ligand 5 and 7 are more hydrophobic in nature as com-
pared to other ligands of class I GKA because of the pres-
ence of additional cyclophenyl and cyclopropyl groups re-
spectively. The binding modes of ligand 5 and 7 are shown 
in Fig. (6). These ligands bind in different mode as compared 
to other ligands of this class because of presence of addi-
tional hydrophobic cyclic groups. Cyclophenyl ring of ligand 
5 shows hydrophobic interaction with His218 and binds in 
hydrophobic pocket 2, this additional interaction lowers 
binding energy approximately by 2 kcal/mol as compared to 
other ligands and makes it more potent GKA. Cyclopropyl 
ring of ligand 7 binds in hydrophobic pocket 3 and shows 
hydrophobic interactions with Met210, Met235 and Tyr214. 
This is the second most potent ligand of class I GKA. Auto-
Dock calculated binding energy of ligand 7 is -9.7 kcal/mol, 
which is 0.4 kcal/mol higher compared to experimental 
value. Experimental EC50 of other ligand of this class is not 
available so it’s hard to compare binding energy estimated 
by autodock. 
Class II: Amide-Based Achiral GKAs 
  This class of GKAs lacks chiral carbon connected to am-
ide group. Multi-substituted cyclic ring is present which acts 
as stem of Y letter and substituents on this ring orient in the 
shape of Y. Lack of chiral carbon center in these ligands 
makes ligands less flexible. Hydrophobic pocket 2 accom-
modates smaller hydrophobic groups while hydrophobic 
pocket 3 accommodates bigger hydrophobic groups. Fig. (7) 
shows binding mode of this class of ligands. This class also 
shows specific hydrogen bond formation with the Arg63 
backbone. Ligands having carboxyl group attached to het-
erocyclic ring shows additional hydrogen bond formation 
with the Arg63 side chain and contributes to the binding en-
ergy. Tyr215 and Gln98 are involved in hydrogen bond for-
mation with ether group. Amino group is present instead of 
ether group in ligand 10 and this amino group also shows 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). A. Binding mode of ligand 5. B. Binding mode of ligand 7. Ligands are shown in ball and stick display. Amino acids are shown in 
line view. Molecular Docking Assessment of Glucokinase Activators  Current Chemical Genomics, 2008, Volume 2    85 
hydrogen bond formation with Tyr215 and Gln98 amino 
acids. Crystal structure of ligand 10 bound at allosteric site 
of GK is present and our docking mode shows similar kind 
of binding interactions as crystal structure.  
Class III: Urea Derivatives GKAs 
  This class of GKAs resembles structurally with class I 
GKAs. Binding modes of the ligands are also similar in ori-
entation as Class I GKAs. This class of ligands also shows 
specific hydrogen bond formations with Arg63 carbonyl O 
and NH to NH of amide and N of thiazole, respectively. R3 
group lies in hydrophobic pocket 3 and makes hydrophobic 
interactions with Val62, Ile159 Met210, Ile211, Met235, 
Val452, amino acid residues. Tyr215 is involved in aro-
matic/hydrophobic interaction at hydrophobic pocket 2 and 
also forms hydrogen bonds with ligands containing hydrogen 
bond acceptor group in R2. Fig. (8) shows binding mode of 
ligand 15.  
Class IV: Miscellaneous GKAs 
  This class of GKAs contains ligands which have some 
unique groups. Ligand 19 and 20 contains cyclopropyl group 
connecting three arms. Docking studies of ligand19 shows 
comparable binding energy to the experimental value. Clus-
tering of docked conformations also gave high confidence, 
95% of the docked conformations fall in one cluster with 1.5 
Å RMSD tolerance. Docking mode and clustering histogram 
of ligand 19 are shown in Fig. (9). Thr65 is involved in hy-
drogen bond formation with O of methyl sulfone group. 
Ligand 18 does not contain amide group, this is structurally 
different from all other ligands. Docking studies of this 
ligand also shows involvement of Arg63 in two specific hy-
drogen bond formation with N of pyridine and carbonyl 
group of carboxylic group of ligand 18 (Fig. 10). This sug-
gests that Arg63 is highly conserved residue which is spe-
cifically involved in hydrogen bond formation with GKAs. 
Hydrophobic interactions for this class were similar to that 
of other classes of GKAs.  
DISCUSSION 
  Docking studies of GKAs identify involvement of Arg63 
as key residue in hydrogen bond formation with all classes of 
ligands. Therefore, for R1 group, a hydrogen bond donor as 
linker and a heterocycle as hydrogen bond acceptor seem the 
best choice. Van der Walls packing interactions contribute 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Binding mode of class II GKAs. A. Aligned binding mode of class II GKAs. B. Binding mode of ligand 9 at the allosteric site of 
GK, there is additional H bond formation between Arg63 side chain and the ligand. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Binding mode of ligand 15 (Class III) at the allosteric site 
of GK. 86    Current Chemical Genomics, 2008, Volume 2  Kumari and Li 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). A. Binding mode of ligand 19 (class IV). B. Clustering of docked conformations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). Binding interactions of ligand 18 (A). Hydrogen bond formation with Arg63 amino acid (B, C). Molecular Docking Assessment of Glucokinase Activators  Current Chemical Genomics, 2008, Volume 2    87 
Table 3A.  Binding Free Energy Comparison Between the Experimental
a Values and AutoDock’s Predicted Values of the Ligands. 
Experimental Values are Converted from EC50 Values in Table 1 
Binding free energy (Gbind) (kcal/mol) 
Ligands  AutoDock (predicted)  Experimental 
7 -9.7  -9.3 
9 -9.4  -9.6 
10 -9.0  -8.5 
13 -9.1  -9.2 
16 -9.3  -6.5 
17 -9.7  -7.1 
18 -8.5  -7.5 
19 -9.3  -9.2 
20 -8.2  -9.2 
21 -7.7  -8.2 
 
Table 3B.  Histogram Showing Experimental and Autodock Predicted Binding Energies (kcal/mol) for Ligands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
most favorably to the binding energies of the ligands. Three 
hydrophobic cavities are formed by van der Walls packing 
interactions between ligand and allosteric site of GK and the 
ligands show three arms consisting of cyclic moieties. Each 
arm packs in the hydrophobic pocket. Ligands having less 
than three arms show less hydrophobic binding interactions 
and will lead to less potency. Val62, Ile159, Met210, Ile211, 
Cys220, Met235, Val452, makes floor of the allosteric bind-
ing site. These hydrophobic residues are exclusively in-
volved in van der Walls packing with all classes of ligands. 
Tyr214 and Tyr215 are involved in both aromatic and hy-
drophobic interactions. Ligands having more favorable inter-
actions with Tyr214 show stronger binding energies as it 
exerts effect on both Pockets 2 and 3. Ligand’s arm having 
longer chain with hydrophobic cyclic ring binds more fa-
vorably in hydrophobic pocket 3 and contributes to the po-
tency of the ligand. R2 group of class II GKAs have two 
arms, longer arm binds in hydrophobic pocket 3 while 
shorter arm binds in hydrophobic pocket 2. Fig. (2) shows 
hydrophobic pockets and binding of class II GKAs to the 
hydrophobic pocket. Ligand 14 shows addition hydrogen 
bond formation between Arg250 and SO2CH3 group of 
ligand. This interaction also increases potency of the ligand. 
Ligands containing terminal carboxylic group show addi-
tional hydrogen bond formation with the Arg63 side chain 
and adds towards binding energy of the activators. R1 and R2 
groups of Ligands 10 and 11 are different but both shows 
similar binding mode and similar binding energy. This could 88    Current Chemical Genomics, 2008, Volume 2  Kumari and Li 
be due to involvement of same amino acid residues in both 
binding interactions. Ligand 8 shows involvement of Thr65 
backbone in the hydrogen bond formation with N of bicyclic 
ring, but this ligand shows lowest binding interactions 
among all classes of GKAs, this could be due to less interac-
tion with the key hydrophobic side chains.  
  Ligand 5 (class I GKA) shows highest binding interac-
tions among all classes of GKAs. This ligand contains ben-
zyl group instead of methyl group of SO2CH3 group of ligand 
1, 6, 14, 16, 17, 19, 20, and 21 and makes unique hydropho-
bic interaction with His218 (Fig. 6A). The Oxygen of meth-
ylsulfonyl (SO2CH3) group forms hydrogen bond with 
Tyr215 and Gln98. All other interactions are similar to other 
members of this class. The binding energy improves over 2 
kcal/mol because of the unique hydrophobic interaction with 
His218. Ligand 7 contains cyclopropyl group instead of ben-
zyl group of ligand 5 in R2 group. It also has tertahydropyran 
group at R3 position and binds in hydrophobic pocket 2. 
Oxygen of tertahydropyran makes favorable hydrogen bond-
ing interactions with Tyr215 and Gln98, and hydrophobic 
interactions of Tyr215, Pro66 and Val455 amino acid resi-
dues. R2 group binds toward hydrophobic pocket 3 and cy-
clopropyl group makes van der Waals packing with Met210 
and Met235. This type of interaction is consistent with 
ligand 14 (class II GKA) interaction. Class II GKAs binding 
shows accommodation of bigger hydrophobic group in hy-
drophobic pocket 3. Ligand 18 is structurally different from 
all classes of ligand, it lacks amide group. This ligand shows 
same kind of hydrogen bond interactions with the Arg63 but 
hydrogen bonding partners are different. Similar kind of in-
teraction with structurally different ligands ascertains that 
Arg63 is specifically involved in hydrogen bond formation 
with GKAs. One structural requirement of GKAs would be 
presence of adjacent hydrogen bond accepter and donor 
group. Ligand 19 and 20 are unique in having tri-substituted 
cyclopropyl ring. Substituents on cyclopropyl ring makes 
arms of the ligands and leave ligands less flexible as com-
pared to class I GKAs. The docking studies of this class of 
ligands shows over 90% conformations in one cluster (Fig. 
9). Ligand 22 resembles class I GKAs, the only difference is 
presence of sulfonyl group instead of carbonyl group. The 
replacement of carbonyl group with sulfonyl group does not 
change much binding interaction pattern with GK. 
Structure Activity Relationship (SAR) Analysis 
  The docking studies gave better insight and understand-
ing on how various allosteric GKAs interact with Glu-
cokinase. This study acknowledges contribution of hydro-
phobic interactions as the most to the binding energies of 
these activators. Hydrophobic and aromatic nature of the 
R1/R2/R3 group is more favorable. Overall, Pocket 2 ac-
commodates the most diverse groups which have aromatic, 
hydrophobic and even hydrophilic substituents. Try215 is the 
key residue involved in aromatic, hydrophobic and hydrogen 
bond forming interactions. Gln98 amino acid residue some-
times also involved in hydrogen bond formation in pocket 2. 
Ile211 and Leu451 are other hydrophobic residues contribut-
ing toward van der Waals packing in pocket 2. Continued 
exploration of Pocket 2 binding is much warranted for more 
optimal GKA design. Aromatic heterocycles and hydrogen 
bond forming linkers seem the choices to build the R2 arm 
of GKA. On the other hand, Pocket 3 is more solvent ex-
posed and seems to have less potential for GKA optimization 
due to interaction/desolvation energy compensation. In con-
clusion, we demonstrate the interactions of GKAs at allos-
teric site at atomic level and the important interactions which 
could be helpful in design of novel glucokinase activator. 
These activators could be very efficient as blood glucose-
lowering agents due to its dual mechanism of augmenting 
islet insulin release and enhancing hepatic glucose disposal. 
The binding interactions and involvement of specific amino 
acid could lead to design of novel glucokinase activator with 
higher selectivity and least side effects for the treatment of 
type 2 diabetes and related disorders. 
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